No Data
No Data
Hold Rating on Spruce Biosciences Amid Clinical Trial Uncertainties and Rising Competition
Spruce Biosciences Faces Nasdaq Delisting Threat Over Low Stock Prices
Buy Rating Affirmed for Spruce Biosciences Amid Upcoming Trial Data and Strong Financial Position
Express News | HC Wainwright & Co. Reiterates Neutral on Spruce Biosciences
Spruce Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 — HC Wainwright & Co. Reiterates → Neutral 03/14/2024 143.9% RBC Capital $9 → $2 Downgrades Ou
Express News | Spruce Biosciences: Cash & Cash Equivalents as of March 31, 2024 Expected to Allow Co to Fund Its Current Operating Plan Through End of 2025